Literature DB >> 15034673

Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes.

Jan Joseph1, Bernd Niggemann, Kurt S Zaenker, Frank Entschladen.   

Abstract

Cell migration is of paramount importance in physiological processes such as immune surveillance, but also in the pathological processes of tumor cell migration and metastasis development. The factors that regulate this tumor cell migration, most prominently neurotransmitters, have thus been the focus of intense investigation. While the majority of neurotransmitters have a stimulatory effect on cell migration, we herein report the inhibitory effect of the endogenous substance anandamide on both tumor cell and lymphocyte migration. Using a collagen-based three-dimensional migration assay and time-lapse videomicroscopy, we have observed that the anandamide-mediated signals for CD8+ T lymphocytes and SW 480 colon carcinoma cells are each mediated by distinct cannabinoid receptors (CB-Rs). Using the specific agonist docosatetraenoylethanolamide (DEA), we have observed that the norepinephrine-induced migration of colon carcinoma cells is inhibited by the CB1-R. The SDF-1-induced migration of CD8+ T lymphocytes was, however, inhibited via the CB2-R, as shown by using the specific agonist JWH 133. Therefore, specific inhibition of tumor cell migration via CB1-R engagement might be a selective tool to prevent metastasis formation without depreciatory effects on the immune system of cancer patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034673     DOI: 10.1007/s00262-004-0509-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  48 in total

Review 1.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 2.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

3.  Cannabinoid Receptor-2 Regulates Embryonic Hematopoietic Stem Cell Development via Prostaglandin E2 and P-Selectin Activity.

Authors:  Virginie Esain; Wanda Kwan; Kelli J Carroll; Mauricio Cortes; Sarah Y Liu; Gregory M Frechette; Lea M V Sheward; Sahar Nissim; Wolfram Goessling; Trista E North
Journal:  Stem Cells       Date:  2015-05-26       Impact factor: 6.277

Review 4.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

Review 5.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 6.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 7.  Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.

Authors:  Esmée Vendel; Elizabeth C M de Lange
Journal:  Neuromolecular Med       Date:  2014-06-15       Impact factor: 3.843

Review 8.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

9.  Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon.

Authors:  Angelo A Izzo; Gabriella Aviello; Stefania Petrosino; Pierangelo Orlando; Giovanni Marsicano; Beat Lutz; Francesca Borrelli; Raffaele Capasso; Santosh Nigam; Francesco Capasso; Vincenzo Di Marzo
Journal:  J Mol Med (Berl)       Date:  2007-09-06       Impact factor: 4.599

10.  Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

Authors:  Maria Teresa Cencioni; Valerio Chiurchiù; Giuseppina Catanzaro; Giovanna Borsellino; Giorgio Bernardi; Luca Battistini; Mauro Maccarrone
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.